1. Medtech Insight
  3. >>Deals

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover news from the TAVI space, ConforMIS’ customized knee implants, and Siemens’ recent companion diagnostic dealmaking.

A new analysis of data from Edwards Lifesciences Corp.’s PARTNER/Cohort A continued access clinical study, presented at the 2012 meeting of the Society of Thoracic Surgeons meeting in Fort Lauderdale, FL, suggests that outcomes are improving for transapical TAVI (transcatheter aortic valve implantation). The findings should help ease previous concerns about the safety and cost-effectiveness of the transapical approach to valve delivery.

The new analysis of 822 patients treated under the PARTNER study’s nonrandomized continued access protocol (CAP), found a substantially lower rate of mortality and stroke in transapical TAVI patients compared...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

More from Business